Patent 9328077 was granted and assigned to Agios Pharmaceuticals on May, 2016 by the United States Patent and Trademark Office.
Compounds and compositions comprising compounds that activate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that activate PKM2 in the treatment of cancer.